FDA Approves New Targeted Therapy Etcamah for Advanced Breast Cancer
A blood test can detect an emerging ESR1 mutation before scans show progression, allowing doctors to switch treatment earlier.
FDA approval of camizestrant, marketed as Etcamah, introduces a new treatment strategy for certain people with advanced HR-positive, HER2-negative breast cancer—combining an oral targeted therapy with early detection of treatment resistance.
For people living with advanced breast cancer, one of the hardest parts of treatment is knowing when a therapy that has been working may be losing its effectiveness.
Cancer cells can change during treatment. In some hormone receptor-positive breast cancers, tumors acquire mutations that allow them to continue growing despite therapies designed to block estrogen signaling.
Now, the U.S. Food and Drug Administration has approved a treatment strategy designed to identify one of those changes earlier.
On September 4, 2026, the FDA granted accelerated approval to Etcamah (camizestrant), made by AstraZeneca, for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer when an ESR1 mutation is detected during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The treatment is given with a CDK4/6 inhibitor.
The FDA also authorized Guardant360 CDx as the companion diagnostic used to identify ESR1 mutations for this treatment.
Why ESR1 mutations matter
Hormone receptor-positive breast cancers use hormone signaling, particularly estrogen signaling, to help fuel their growth. Aromatase inhibitors are commonly used to reduce the body’s estrogen production.
But cancer is not static.
During treatment, some tumors can acquire changes in the ESR1 gene, which provides instructions for the estrogen receptor. These mutations can contribute to resistance to aromatase inhibitors.
That creates a difficult clinical problem: a treatment may still be controlling the disease, but cancer cells carrying a resistance mutation may already be emerging.
The new Etcamah strategy attempts to intervene at that molecular stage rather than waiting for progression to become apparent on imaging.
The blood test behind the new approach
The FDA describes this as the first cancer therapy approval guided by detection of a resistance mutation in circulating tumor DNA before imaging tests show that the disease is progressing.
The companion test looks for tiny fragments of DNA released by tumor cells into the bloodstream. This material is known as circulating tumor DNA, or ctDNA.
For eligible patients, detecting an ESR1 mutation through the blood test can provide doctors with information that may not yet be visible on a CT or other imaging study.
That does not mean a blood test replaces scans. Instead, it adds another layer of information about what the cancer may be doing at a molecular level.
This distinction is important because the FDA approval is specifically tied to detecting an ESR1 mutation during ongoing first-line treatment, before documented radiographic progression.
What did the clinical trial find?
The approval was supported by results from the SERENA-6 randomized clinical trial.
The study included 315 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors developed detectable ESR1 mutations while they were receiving an aromatase inhibitor together with a CDK4/6 inhibitor.
Patients were randomly assigned either to switch their endocrine treatment to camizestrant while continuing a CDK4/6 inhibitor or to continue their aromatase inhibitor with a CDK4/6 inhibitor.
The difference in progression-free survival was substantial.
Median progression-free survival was 16 months in the camizestrant group compared with 9.2 months in the aromatase-inhibitor group. The FDA reported a hazard ratio of 0.44, meaning the trial showed a lower risk of disease progression or death during the study period in the camizestrant group.
However, overall-survival data were not yet mature when the FDA evaluated the progression-free-survival results.
What does accelerated approval mean?
The word “approved” is important—but so is the word accelerated.
The FDA granted Etcamah accelerated approval based on progression-free survival, while requiring additional research to verify and describe clinical benefit. The ongoing requirements include further analyses from SERENA-6 and another randomized study comparing different treatment strategies.
In other words, researchers still need to establish how the early treatment switch affects longer-term outcomes, including overall survival.
This is particularly important because detecting a resistance mutation earlier is biologically promising, but earlier intervention does not automatically guarantee that patients will live longer.
What are the safety concerns?
Etcamah is an oral medication, but “a daily pill” does not mean a treatment without risks.
The FDA prescribing information includes a boxed warning concerning the risk of QTc interval prolongation and abnormal heart rhythms when camizestrant is used with certain medications that also prolong the QT interval. The FDA also lists warnings concerning slow heart rate and embryo-fetal toxicity.
This makes medication review and medical monitoring particularly important for patients receiving treatment for advanced cancer.
The FDA-approved dose is 75 mg once daily in combination with a CDK4/6 inhibitor, but treatment decisions and dosing belong to the patient’s oncology team.
A broader shift in cancer treatment
The significance of Etcamah goes beyond one new medicine.
The approval illustrates a growing movement toward molecular monitoring of cancer. Instead of relying exclusively on symptoms and imaging, doctors can increasingly examine genetic signals circulating in the bloodstream.
For patients with advanced breast cancer, that could eventually mean treatment decisions are made not only according to where tumors are and how large they are, but also according to how their biology is changing.
That approach is still evolving.
Etcamah does not apply to every person with breast cancer, and an ESR1 mutation does not automatically mean this treatment is appropriate. The FDA indication is specifically defined around HR-positive, HER2-negative locally advanced or metastatic disease, ongoing aromatase-inhibitor/CDK4/6 therapy and ESR1 mutation detection using an authorized test.
For eligible patients, however, the approval represents a notable change in how treatment resistance can be detected and addressed.
The larger story is not simply about a new pill. It is about catching cancer’s molecular changes earlier—and using that information to make treatment more responsive to the disease as it evolves.
Photo by Bermix Studio on Unsplash
About Wellcore Weekly: Wellcore Weekly covers health, wellness, nutrition, sleep, fitness, and medical research with timely, easy-to-understand updates for everyday readers.
